NEW YORK (GenomeWeb News) – UK molecular diagnostics company Enigma Diagnostics said today that it has licensed access to an Applied Biosystems patent for real-time detection of nucleic acid amplification products.
The Porton Down, UK-based company, which specializes in decentralized and point-of-care diagnostics, said it has licensed access to US Patent No. 5,928,907, “System for real time detection of nucleic acid amplification products.”
Enigma said that it is the third license agreement it has signed with ABI and that the technology complements its license under other patents owned by Applied Biosystems for real-time PCR thermal cyclers.
Enigma also said that this is the first license ABI has granted to the methods claimed under the ‘907 patent.
Financial terms of the agreement were not released.